Analyst Geulah Livshits works at CHARDAN CAPITAL and is focused on the Healthcare sector with 117 price targets and ratings documented since 2019 spanning on 19 stocks. Analyst's average stock valuation to be materialised ratio is 26.65% with an average time for price targets to be met of 65.53 days.
Most recent stock forecast was given on PRVB, Provention Bio, Inc at 21-Nov-2022.
Geulah Livshits best performing recommendations are on NTLA (INTELLIA THERAPEUTICS, INC).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS, INC) at 6/25/2021. The price target of $130 was fulfilled within 3 days with a profit of $41.17 (46.35%) receiving and performance score of 154.49.
Average potential price target upside